MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Cytek Biosciences Inc

Slēgts

SektorsVeselības aprūpe

5.39 -3.92

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

5.38

Max

5.48

Galvenie mērījumi

By Trading Economics

Ienākumi

105K

-5.5M

Pārdošana

6.7M

52M

EPS

-0

Peļņas marža

-10.476

Darbinieki

692

EBITDA

6.4M

-4.2M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+10.97% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 26. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

240M

742M

Iepriekšējā atvēršanas cena

9.31

Iepriekšējā slēgšanas cena

5.39

Ziņu noskaņojums

By Acuity

17%

83%

18 / 361 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

Cytek Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 16. janv. 23:29 UTC

Karstas akcijas

Stocks to Watch: Atossa Therapeutics, Union Pacific

2026. g. 16. janv. 22:48 UTC

Iegādes, apvienošanās, pārņemšana

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

2026. g. 16. janv. 22:43 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

2026. g. 16. janv. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

2026. g. 16. janv. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 16. janv. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Auto & Transport Roundup: Market Talk

2026. g. 16. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 16. janv. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 16. janv. 21:48 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

2026. g. 16. janv. 21:41 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

2026. g. 16. janv. 21:38 UTC

Iegādes, apvienošanās, pārņemšana

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

2026. g. 16. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

2026. g. 16. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

2026. g. 16. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

2026. g. 16. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

2026. g. 16. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

2026. g. 16. janv. 20:44 UTC

Peļņas

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

2026. g. 16. janv. 20:42 UTC

Tirgus saruna

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

2026. g. 16. janv. 20:28 UTC

Tirgus saruna

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

2026. g. 16. janv. 19:12 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

2026. g. 16. janv. 18:53 UTC

Tirgus saruna

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

2026. g. 16. janv. 18:41 UTC

Tirgus saruna

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

2026. g. 16. janv. 18:31 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

2026. g. 16. janv. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 16. janv. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 16. janv. 17:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 16. janv. 17:03 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 16. janv. 17:03 UTC

Tirgus saruna

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

2026. g. 16. janv. 16:32 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

2026. g. 16. janv. 16:20 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Cytek Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

10.97% augšup

Prognoze 12 mēnešiem

Vidējais 6.17 USD  10.97%

Augstākais 7.5 USD

Zemākais 5 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cytek Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

2

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

3.7 / 3.8Atbalsts un pretestība

Īstermiņā

Weak Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

18 / 361 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat